http://www.japancorp.netJCN Newswire - Recent Headline Newsen-usCopyright 2013, JCN Newswire10http://www.japancorp.net/images/jcnxml.jpghttp://www.japancorp.net8831JCN Newswirehttp://www.japancorp.net/press_release/26736/astar_and_cytos_bring_singapores_first_influenza_vaccine_to_clinical_testinghttp://www.japancorp.net/press_release/26736/astar_and_cytos_bring_singapores_first_influenza_vaccine_to_clinical_testingSingapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle (VLP) technology.Fri,17 May 2013 12:55:34 +0000http://www.japancorp.net/press_release/26661/astar_and_veredus_laboratories_create_markets_first_labonchip_for_the_detection_of_multiple_tropical_infectious_diseaseshttp://www.japancorp.net/press_release/26661/astar_and_veredus_laboratories_create_markets_first_labonchip_for_the_detection_of_multiple_tropical_infectious_diseasesA*STAR and Veredus Laboratories Create Market's First Lab-on-Chip for the Detection of Multiple Tropical Infectious DiseasesThu,25 Apr 2013 22:00:24 +0000http://www.japancorp.net/press_release/26643/understanding_abnormal_proteins_in_degenerative_diseaseshttp://www.japancorp.net/press_release/26643/understanding_abnormal_proteins_in_degenerative_diseasesUnderstanding Abnormal Proteins in Degenerative DiseasesMon,22 Apr 2013 19:39:24 +0000http://www.japancorp.net/press_release/26628/singapore_scientist_wins_coveted_chen_new_investigator_award_2013http://www.japancorp.net/press_release/26628/singapore_scientist_wins_coveted_chen_new_investigator_award_2013Singapore Scientist Wins Coveted Chen New Investigator Award 2013Thu,18 Apr 2013 12:29:25 +0000http://www.japancorp.net/press_release/26627/astar_scientists_decipher_genome_code_of_a_living_fossilhttp://www.japancorp.net/press_release/26627/astar_scientists_decipher_genome_code_of_a_living_fossilA*STAR Scientists Decipher Genome Code of a Living FossilThu,18 Apr 2013 12:29:24 +0000http://www.japancorp.net/press_release/26617/connell_brothers_appoints_president_of_wilburellis_co_japanhttp://www.japancorp.net/press_release/26617/connell_brothers_appoints_president_of_wilburellis_co_japanConnell Brothers, a division of Wilbur-Ellis Company, and the largest marketer and distributor of specialty chemicals and industrial ingredients in Asia-Pacific, has appointed Mr. Iguchi Shinichi, former head of marketing and business development of monomer at Sumitomo Chemicals, based in China, to lead the strategic direction and expand the business operations of Wilbur-Ellis Co. Japan.Wed,17 Apr 2013 10:50:24 +0000http://www.japancorp.net/press_release/26603/rigid_growth_matrix_a_key_to_success_of_cardiac_tissue_engineeringhttp://www.japancorp.net/press_release/26603/rigid_growth_matrix_a_key_to_success_of_cardiac_tissue_engineeringRigid Growth Matrix: A Key to Success of Cardiac Tissue EngineeringFri,12 Apr 2013 23:54:24 +0000http://www.japancorp.net/press_release/26582/eisai_announces_preclinical_research_findings_suggesting_novel_infibitory_effect_on_tumor_metastasis_for_anticancer_agent_halavenr_at_aacr_104th_annual_meetinghttp://www.japancorp.net/press_release/26582/eisai_announces_preclinical_research_findings_suggesting_novel_infibitory_effect_on_tumor_metastasis_for_anticancer_agent_halavenr_at_aacr_104th_annual_meetingEisai Co., Ltd. announced today that it has presented preclinical research findings suggesting a potential inhibitory effect on tumor metastasis as a possible novel mechanism of action for anticancer agent Halaven(R) (eribulin mesylate, "eribulin") at the American Association for Cancer Research (AACR) 104th Annual Meeting.Wed,10 Apr 2013 17:45:38 +0000http://www.japancorp.net/press_release/26563/eisai_coestablishes_the_global_health_innovative_technology_fundhttp://www.japancorp.net/press_release/26563/eisai_coestablishes_the_global_health_innovative_technology_fundEisai Co., Ltd. has co-established the Global Health Innovative Technology Fund (GHIT Fund) to advance the research and development of new medicines, vaccines, and diagnostics from Japan to fight infectious diseases in emerging countries and the developing world.Mon,8 Apr 2013 15:37:34 +0000http://www.japancorp.net/press_release/26559/eisai_establishes_pharma_sales_subsidiary_in_moscow_ahead_of_planned_direct_sales_launch_in_russiahttp://www.japancorp.net/press_release/26559/eisai_establishes_pharma_sales_subsidiary_in_moscow_ahead_of_planned_direct_sales_launch_in_russiaEisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Moscow, Russia, which will be named Limited Liability Company Eisai ("Eisai Russia"). Eisai Russia will function as a direct subsidiary of Eisai's U.K. pharmaceutical operation, Eisai Europe Ltd.Fri,5 Apr 2013 15:57:12 +0000